Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2023-000224-10
    Sponsor's Protocol Code Number:PBKV.5zdnia03.08.2022
    National Competent Authority:Poland - Office for Medicinal Products
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2023-04-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPoland - Office for Medicinal Products
    A.2EudraCT number2023-000224-10
    A.3Full title of the trial
    A randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of a 12-week
    dose of 35 mg DHEA on quality of life in menopausal women.
    Randomizowane, podwójnie zaślepione, kontrolowane placebo, wieloośrodkowe badanie oceny wpływu 12-tygodniowego stosowania DHEA w dawce 35 mg na jakość życia kobiet w wieku menopauzalnym.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of a 12-week
    dose of 35 mg DHEA on quality of life in menopausal women.
    Randomizowane, podwójnie zaślepione, kontrolowane placebo, wieloośrodkowe badanie oceny wpływu 12-tygodniowego stosowania DHEA w dawce 35 mg na jakość życia kobiet w wieku menopauzalnym.
    A.3.2Name or abbreviated title of the trial where available
    DHEA/EPH/02/2022
    A.4.1Sponsor's protocol code numberPBKV.5zdnia03.08.2022
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorThe Pharmaceutical Company LEK-AM Sp. Zo.o.
    B.1.3.4CountryPoland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportN/A
    B.4.2CountryPoland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEuropharma M. Rachtan Sp. z o.o.
    B.5.2Functional name of contact point CRO Clinical Trial
    B.5.3 Address:
    B.5.3.1Street AddressKrzywa 6
    B.5.3.2Town/ cityKatowice
    B.5.3.3Post code40-061
    B.5.3.4CountryPoland
    B.5.4Telephone number+4832 786 40 50
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Biosteron 10 mg, Biosteron 25 mg
    D.2.1.1.2Name of the Marketing Authorisation holderThe Pharmaceutical Company LEK-AM Sp. z o.o.
    D.2.1.2Country which granted the Marketing AuthorisationPoland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDHEA
    D.3.2Product code PR1-888-2022; PR2-888-2022
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Menopause
    Menopauza
    E.1.1.1Medical condition in easily understood language
    Menopause
    Menopauza
    E.1.1.2Therapeutic area Health Care [N] - Population Characteristics [N01]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Demonstration that 12-week supplementation with 35 mg DHEA improves quality
    of life and reduces symptoms of vaginal atrophy.
    Demonstration that DHEA supplementation at a dose of 35 mg improves mood and reduces the
    severity of vasomotor symptoms associated with menopause.
    Wykazanie, że 12-tygodniowa suplementacja DHEA w dawce 35 mg poprawia jakość życia i zmniejsza objawy atrofii pochwy.
    Wykazanie, że suplementacja DHEA w dawce 35 mg poprawia nastrój i zmniejsza nasilenie objawów naczynioruchowych związanych z menopauzą.
    E.2.2Secondary objectives of the trial
    Demonstration that DHEA supplementation in a dose of 35 mg affects the
    concentration of DHEA and estradiol.
    Wykazanie, że suplementacja DHEA w dawce 35 mg wpływa na stężenie DHEA i estradiolu.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - woman,
    -BMI 20.0-29.9 kg / m2,
    - time from the last menstruation at least 12 months,
    -stable body weight during the last 6 months,
    - FSH concentration 35-135 mIU / ml and estradiol 5-55 pg / ml,
    - concentration of total testosterone 0.084 - 0.481 ng / ml,
    - Beck Depression Score 11–27 points,
    - result in the Kupperman Scale 17-30 points,
    - declared sexual activity,
    - FSFI scale
    - not using menopausal replacement therapy for at least 6 months,
    - The ability to understand audit procedures and provide written informed consent
    kobieta,
    BMI 20,0-29,9 kg/m2,
    czas od ostatniej miesiączki co najmniej 12 miesięcy,
    stabilna masa ciała w czasie ostatnich 6 miesięcy,
    stężenie FSH 35-135 mIU/ml i estradiol 5-55 pg/ml,
    stężenie testosteronu całkowitego 0,084 - 0,481 ng/ml,
    wynik w skali depresji Becka 11–27 punktów,
    wynik w Skala Kuppermana 17-30 punktów,
    deklarowana aktywność seksualna,
    skala FSFI
    nie stosowanie menopauzalnej terapii zastępczej od co najmniej 6 miesięcy,
    umiejętność zrozumienia procedur badania i udzielenie pisemnej świadomej zgody.

    E.4Principal exclusion criteria
    - Current use of menopausal replacement therapy,
    - The use of phytoestrogens,
    - The use of psychotropic drugs,
    - Use of oral or intravenous glucocorticosteroids,
    - Vaginal application of DHEA (Prasteron),
    - Current or history of oncological disease,
    - Decompensated thyroid disease or other endocrine disease such as Cushing's syndrome
    - Uncontrolled cardiovascular diseases (hypertension, coronary artery disease, heart failure),
    - Osteoarthritis with significant pain ailments with the use of steroid therapy,
    - Rheumatoid arthritis and other rheumatological diseases with the use of steroids,
    - A disease of the nervous system that may affect the quality of life,
    - History of mental illness (except postmenopausal depression),
    - The patient's lack of cooperation
     Aktualne stosowanie menopauzalnej terapii zastępczej,
     Stosowanie fitoestrogenów,
     Stosowanie leków psychotropowych,
     Stosowanie glikokortykosteroidów doustnie lub dożylnie,
     Dopochwowe stosowanie DHEA (Prasteron),
     Choroba onkologiczna obecnie lub w wywiadzie,
     Niewyrównana choroba tarczycy lub inna choroba endokrynna, np. zespół Cushinga,
     Niekontrolowane choroby sercowo-naczyniowe (nadciśnienie tętnicze, choroba wieńcowa, niewydolność serca),
     Choroba zwyrodnieniowa stawów ze znacznymi dolegliwościami bólowymi z zastosowaniem sterydoterapii,
     Reumatoidalne zapalenie stawów i inna choroba reumatologiczna z zastosowaniem sterydoterapii,
     Choroba układu nerwowego mogąca wpływać na jakość życia,
     Choroba psychiczna w wywiadzie (oprócz depresji pomenopauzalnej),
     Brak współpracy pacjentki
    E.5 End points
    E.5.1Primary end point(s)
    Demonstration that 12 weeks of supplementation with 35 mg DHEA improves quality of sexual
    life and reduces symptoms of vaginal atrophy.
    Demonstration that DHEA supplementation at a dose of 35 mg improves mood and reduces the
    severity of vasomotor symptoms associated with menopause.
    Wykazanie, że 12 tygodniowa suplementacja DHEA w dawce 35 mg poprawia jakość życia seksualnego i zmniejsza objawy atrofii pochwy.
    Wykazanie, że suplementacja DHEA w dawce 35 mg poprawia nastrój i zmniejsza nasilenie objawów naczynioruchowych związanych z menopauzą.
    E.5.1.1Timepoint(s) of evaluation of this end point
    N/A
    nie dotyczy
    E.5.2Secondary end point(s)
    Demonstration that 35 mg DHEA supplementation
    affects serum levels of LH, DHEAS and estradiol
    Wykazanie, że suplementacja DHEA w dawce 35 mg wpływa na stężenia w surowicy LH, DHEAS i estradiolu.
    E.5.2.1Timepoint(s) of evaluation of this end point
    N/A
    nie dotyczy
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis Yes
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state100
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    N/A
    nie dotyczy
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-08-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-08-03
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 13:21:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA